


Empagliflozin improves HbA1c in young people with T2DM

March 21 2023, by Elana Gotkine



For young people, empagliflozin is associated with improvement in

glycated hemoglobin (HbA1c), according to a study published in the March issue of *The Lancet Diabetes & Endocrinology*.

Lori M. Laffel, M.D., from Harvard Medical School in Boston, and colleagues conducted a [placebo](#)-controlled trial in 108 centers in 15 [countries](#) involving participants with type 2 diabetes (aged 10 to 17 years) previously treated with metformin or insulin. During April 26, 2018, through May 26, 2022, participants were randomly assigned to oral empagliflozin 10 mg, oral linagliptin 5 mg, or placebo (52, 53, and 53 participants, respectively). Those in the empagliflozin group who did not have HbA1c

Citation: Empagliflozin improves HbA1c in young people with T2DM (2023, March 21) retrieved 14 July 2023 from <https://medicalxpress.com/news/2023-03-empagliflozin-hba1c-young-people-t2dm.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--